Approval · Notice of Compliance 11933 · 2010
BICALUTAMIDE TABLETS USP: Notice of Compliance 11933
Issued December 16, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11933
- Date
- December 16, 2010
- Company
- Fresenius Kabi Oncology Plc
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Non-steroidal antiandrogen
- Canadian reference product
- CASODEX (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BICALUTAMIDE TABLETS USP | 02360098 | Cancelled Pre Market |
Medicinal ingredients
- BICALUTAMIDE 50 MG per TAB